Avid Bioservices Inc (CDMO)

[biopharm]

The 4TH International Conference on Notch Targeting in Cancer
Date: June 25-27, 2014
Venue: Santa Marina Hotel, Mykonos, Greece

The fourth annual international conference devoted to Notch Biology and related Cancer Therapeutics will include basic and translational research, preclinical and clinical studies,
biomarker discovery and progress achieved thus far in this emerging and exciting field of targeting Notch, as examined and presented by leading scientists in the
field. Examples of speakers and preliminary topics include:

Dmitry Gabrilovich, The Wistar Institute, USA:

Effects of Notch Signaling on Regulation of Myeloid Cell
Differentiation in Cancer

http://www.cancerconferences.org/annual_meetings/PRELIMINARY-ANNOUNCEMENT-2014-conferences.pdf

I believe that the change in "Notch Signaling" does have a direct tie towards how Bavi targets "flipped-PS" ... but am trying to determine and look for "exact" wording from Dr. Dmitry Gabrilovich, though I need one of the more scientific minds to look at this possibly? It looks to me like Dr. Gabrilovich is increasing the awareness of how vital "targeting flipped-PS" actually may be.... but referring to "Notch" signaling... ? I could be wrong...

-------------------------------------------------------------

Inhibition of Notch signaling was caused by the disruption of the interaction between Notch receptor and transcriptional repressor CSL, which is normally required for efficient transcription of target genes. This disruption was the result of serine phosphorylation of Notch. We demonstrated that increased activity of casein kinase 2 (CK2) observed in HPC and in MDSC could be responsible for the phosphorylation of Notch and downregulation of Notch signaling. Inhibition of CK2 by siRNA or by pharmacological inhibitor restored Notch signaling in myeloid cells and substantially improved their differentiation, both in vitro and in vivo. This study demonstrates a novel mechanism regulation of Notch signaling in cancer. This may suggest a new perspective for pharmacological regulation of differentiation of myeloid cells in cancer.

http://yourcancer.info/cancer-types/thyroid-cancer/notch-and-myeloid-cells-in-cancer/

---------------------------------------------------------------

1) Dr. Dmetri Gabrilovich is in Mykonos on June 25-27 speaking on "Noth Targeting in Cancer"...

2) the section above I highlighted in red "Inhibition of CK2 by siRNA or by pharmacological inhibitor" ..... IS THIS "Pharmacological inhibitor" ?? possibly end up being the targeting of flipped-PS by Bavituximab ??? in other words.... is Dr. Dmitry Gabrilovich silently hinting at the powers of Bavi, though from another angle for the medical community to understand?

3) I bring this up as I read this section below from Wiki...and take note of the "..hundreds of such antibodies are now available" but Bavituximab is the one that targets "flipped-PS", which just may be considered the breakthrough discovery of all cancer resesarch... and gives some chance that a last minute buyout offer could come when many others do determine this to be true and accepted .... "and" put to practice.

---------------------------------------------------------------

Detection and characterization

Antibodies can be used as powerful tools to detect whether a protein is phosphorylated at a particular site. Antibodies bind to and detect phosphorylation-induced conformational changes in the protein. Such antibodies are called phospho-specific antibodies; hundreds of such antibodies are now available.[20] They are becoming critical reagents both for basic research and for clinical diagnosis.

http://en.wikipedia.org/wiki/Phosphorylation